Observational Study
Copyright ©The Author(s) 2022.
World J Gastroenterol. Jan 14, 2022; 28(2): 242-262
Published online Jan 14, 2022. doi: 10.3748/wjg.v28.i2.242
Table 1 Demographic characteristics of the study population, n (%)
Variable
Helicobacter pylori (+ve)
Helicobacter pylori (-ve)
Total
P value
n = 61
n = 61
n = 122
Mean age in yr ± Standard deviation (range)44.00 ± 16.99 (15-85)44.74 ± 18.10 (17-89)44.37 ± 17.48 (15-89)0.91841
GenderMale36 (50.00)36 (50.00)72 (59.02)1.0000
Female25 (50.00)25 (50.00)50 (40.98)
ResidenceUrban24 (44.44)30 (55.56)54 (44.26)0.3622
Rural37 (54.41)31 (45.59)68 (55.74)
HospitalPublic21 (33.87)31 (49.21)52 (41.60)0.0667
Private41 (58.57)29 (41.43)70 (57.38)
Table 2 Gastric pathologies of the study population, n (%)
Endoscopy results
n (%)
Helicobacter pylori (+ve)
Helicobacter pylori (-ve)
P value1
Normal gastric findings9 (7.40)4 (6.45)5 (7.94)0.2686
Esophagitis4 (3.30)3 (4.80)1 (1.59)
Esophageal varices6 (4.90)1 (1.61)5 (7.94)
Gastritis55 (45.10)28 (45.16)27 (42.86)
Duodenitis6 (4.90)3 (4.84)3 (4.76)
Peptic ulcer27 (22.13)17 (27.42)10 (15.87)
Cancer15 (12.30)5 (8.20)10 (16.4)
Total122 (100)61 (50.00)61 (50.00)
Table 3 Nucleotide variations in the 5’-regulatory (-584 to +107) region of tumor necrosis alpha in Sudanese Helicobacter pylori-infected patients
SNP
Event
SNP locus1
Chromosomeposition
Serialnumber (rs)
C>G (homozygous)Transversion-567NG_007462.1:g.4422 C>Grs2857711
G>A (heterozygous)Transition-375NG_007462.1:g.4614 G>Ars1800750
G>A (heterozygous and homozygous)Transition-307NG_007462.1:g.4682 G>Ars1800629
G>A (heterozygous)Transition-237NG_007462.1:g.4752 G>Ars361525
T>A (heterozygous)Transversion-76NG_007462.1:g.4913 T>Ars41297589
A>T (heterozygous)Transversion+27NG_007462.1:g.5016 A>T2-
Insertion of C-+70NG_007462.1:g.5058-5059 InsC-
Table 4 Overview of the in silico predicted tumor necrosis factor-alpha promoter regions for the respective prediction programs. The most predicted region is indicated in bold
Prediction program
Predicted promoter regions1
BDGP (NNPP version 2.2)2-40 to +10
Promoter 2.0 Prediction Serverno promoter
FPROM +5
TSSG3-146
TSSW4-140
+6
Table 5 Summary of the in silico predicted transcription factor binding sites for tumor necrosis factor-alpha (-146 to +10) region
TranscriptionFactorPosition1
SNP in binding siteSoftware
Start
End
AliBaba2.1
Alggen Promo
Tfsitescan
TF-Binding
GPMiner
Elk-1-145-130X2X
Sp1 -138-126XX
AP-2-129-118XX
Ets-1-118-111X
PEA3/ Ets-1-118-110X
T3R_TRE1-115-108XXX
TNF-alpha-CRE-11292XX
C/EBP-beta-100-74rs41297589 [-76]3XX
NF-kappaB-99-86XX
AP-1-67-57X
NF-kappaB-55-46rs765073823 [-48]rs537401710 [-47]X
Sp1-54-41rs765073823 [-48]rs537401710 [-47]XXX
Sp1 -48-39rs765073823 [-48]rs537401710 [-47]XXX
GATA-40-30rs539666421 [-38]XXX
AP-2-38-27rs539666421 [-38]XXX
TBP-29-20XXX
Table 6 Overview of conserved transcription factor binding sites predicted by multiple-sequence local alignment and visualization
Transcription Factor
Binding sequence
Position1
Conserved SNPs
Start
End
V$CETS168_Q6gCTTCCTC-115-108
V$ETS_Q6gcTTCCtc-115-108
V$SP1_Q4_01ttccCCGCCCtcc-51-39rs765073823 [-48]rs537401710 [-47]
V$SP1_Q6_01tcCCCGCCCt-50-41rs765073823 [-48]rs537401710 [-47]
V$SP1_Q2_01cCCCGCCCtc-49-40rs765073823 [-48]rs537401710 [-47]
Table 7 Summary of the in silico predicted composite regulatory elements for the -146 to +10 region of tumor necrosis factor-alpha
Composite element
MatrixName for a 1st element
Score, strand
Distance in between
MatrixName for a 2nd element
Score, strand
Position of CE, orientation
orientation
Composite score
P value
Sequence
CE00266V$ETS_Q60.991+12V$AP1_Q2_010.831+-118+01.08e-03GCTTCCTCCagaTGAGCTCATGGG
CE00109V$AP1_C0.853-8V$NFAT_Q60.943--66-0.0073.42e-03TTGAATGATTCTTTCCCCGC
CE00150V$AP1_C0.853-8V$NFAT_Q60.943--66--0.2373.42e-03TTGAATGATTCTTTCCCCGC
CE00058V$HMGIY_Q60.955--5V$NFKB_Q6_010.759--78--0.096.89e-03GTTTTCCGCTG
CE00058V$HMGIY_Q60.955--4V$NFKB_Q6_010.662--78-0.0059.20e-03GTTTTCCGCTGG
CE00064V$HNF3_Q60.780+15V$NF1_Q60.956+-28+-0.2544.83e-02ACATATAAAGGCAGtTGTTGGCACACCCAGCCA
Table 8 Allele and genotype frequencies of tumor necrosis factor-alpha-1030 polymorphism among Helicobacter pylori-infected and uninfected subjects and their contributions to Helicobacter pylori infection, n (%)

H. pylori (+ve), n = 61
H. pylori (-ve), n = 61
P value
OR (95%CI)
Allele frequency
TNF-A-1030-T88 (72.13)98 (80.33)0.1760.63 (0.349-1.151)
TNF-A-1030-C34 (27.87)24 (19.67)
Genotype frequency
T/T32 (52.46)43 (70.49)-1 (reference)
T/C24 (39.34)12 (19.67)0.020a2.69 (1.17-6.17)
C/C5 (8.20)6 (9.84)0.8621.12 (0.31-3.99)
Table 9 Multivariate analysis of genotype frequencies of tumor necrosis factor-alpha-1030 polymorphism and sociodemographic characteristics in Helicobacter pylori infection
Variables
P value
OR (95%CI)
Age 0.9460.99 (0.98-1.02)
GenderMale1 (reference)
Female0.8450.93 (0.42-2.02)
ResidenceUrban1 (reference)
Rural0.3411.46 (0.67-3.18)
HospitalPrivate1 (reference)
Public0.04510.45 (0.21-0.98)
Genotype frequencyT/T1 (reference)
T/C0.016a2.87 (1.22-6.78)
C/C0.9821.02 (0.27-3.88)
Table 10 Tumor necrosis factor-alpha-1030 polymorphism and gastric cancer association risk in gastric cancerous patients and subjects with benign gastric disorders, n (%)

Gastric pathologies
OR (95%CI)
Benign disorders1 , n = 108
Cancer, n = 14
Allele frequency
TNF-A-1030-T176 (90.28)21 (75.00)1.150 (0.4627 - 2.8600)
TNF-A-1030-C51 (9.72)7 (25.00)
P value0.8116
Genotype frequency
T/T68 (62.96)7 (50.00)1.700 (0.5556 - 5.2020)
C carrier40 (37.04)7 (50.00)
P value0.3900